Paratek Pharmaceuticals Inc
F:N4CN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Paratek Pharmaceuticals Inc
Pre-Tax Income
Paratek Pharmaceuticals Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Paratek Pharmaceuticals Inc
F:N4CN
|
Pre-Tax Income
-$62.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-13%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Pre-Tax Income
$24.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Pre-Tax Income
$9.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Pre-Tax Income
$7.5B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Pre-Tax Income
$21.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
29%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Pre-Tax Income
$25.7B
|
CAGR 3-Years
56%
|
CAGR 5-Years
29%
|
CAGR 10-Years
25%
|
|
Paratek Pharmaceuticals Inc
Glance View
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 207 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The firm's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.
See Also
What is Paratek Pharmaceuticals Inc's Pre-Tax Income?
Pre-Tax Income
-62.6m
USD
Based on the financial report for Jun 30, 2023, Paratek Pharmaceuticals Inc's Pre-Tax Income amounts to -62.6m USD.
What is Paratek Pharmaceuticals Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-13%
Over the last year, the Pre-Tax Income growth was 27%. The average annual Pre-Tax Income growth rates for Paratek Pharmaceuticals Inc have been 17% over the past three years , 9% over the past five years , and -13% over the past ten years .
